News
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Alongside her husband, Bob Duggan, Maky Zanganeh has guided cancer drug developer Summit Therapeutics to reach staggering new ...
Shares of Summit Therapeutics surged 9.7% to $25.81 in morning trade. The Menlo Park, California-based drug developer did not immediately respond to Reuters' request seeking comment, ...
Summit Therapeutics paid $474.9 million and 10 million of its shares for these rights. It will also owe Akeso various milestones and royalties. This move turned out to be genius.
Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a note issued ...
Zacks Investment Research on MSN3d
Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to TradeShares of Summit Therapeutics PLC (SMMT) have gained 2.8% over the past four weeks to close the last trading session at $21.2 ...
Second, SoFi could grow its revenue even without expanding its membership base, by cross-selling additional products to its ...
Revolution Medicines and Summit Therapeutics entered into a clinical collaboration in multiple solid-tumor settings to evaluate their respective treatments in combination with each other. Redwood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback